Last $6.08 USD
Change Today -0.91 / -13.02%
Volume 4.8M
ECYT On Other Exchanges
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (ECYT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $33.70
52 Week Low
07/29/14 - $5.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENDOCYTE INC (ECYT)

endocyte inc (ECYT) Related Businessweek News

No Related Businessweek News Found

endocyte inc (ECYT) Details

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is primarily developing vintafolide, a SMDC that targets the platinum-resistant ovarian cancer, non-small cell lung cancer, triple negative breast cancer, and carboplatin/paclitaxel combination; and etarfolatide, a proprietary companion imaging agent for vintafolide. The company is also developing product candidates for colorectal, prostate, kidney, endometrial, solid tumors, and other cancers, as well as for chronic inflammatory disorders. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

91 Employees
Last Reported Date: 03/5/14
Founded in 1995

endocyte inc (ECYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $722.0K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $212.2K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $434.4K
Vice President of Clinical Affairs
Total Annual Compensation: $435.6K
Vice President of Research
Total Annual Compensation: $367.8K
Compensation as of Fiscal Year 2013.

endocyte inc (ECYT) Key Developments

Endocyte, Inc. - Special Call

To discuss the TARGET trial results

Endocyte, Inc. Announces Small Molecule Drug Conjugate

Endocyte, Inc. announced that the small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel extended overall survival (OS) for patients with folate receptor (FR) positive recurrent non-small cell lung cancer (NSCLC) compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The data show that patients in the predefined adenocarcinoma subgroup treated with the vintafolide plus docetaxel combination had a 27% reduction in risk of the disease worsening or death (HR=0.73, p=0.0899, one-sided test), and a 30% reduction in the risk of death (HR=0.70, p=0.1018) compared to docetaxel monotherapy. Stratified analysis, which adjusts for pre-defined patient characteristics in the trial, reflect a 49% reduction in the risk of death in patients with adenocarcinoma (HR=0.51, p=0.0147). These data include approximately 78% of the targeted number of events in the overall survival analysis. Overall survival in all patients, including those with squamous disease, reflect a 12% reduction in the risk of death (HR=0.88, p=0.2874) or 25% reduction when stratified (HR=0.75, p=0.1066). The primary endpoint of the study, as presented previously, showed that risk of disease worsening or death (progression-free survival, or PFS) was reduced by 25% for patients who received vintafolide plus docetaxel (HR=0.75, p=0.0696).

Brower Piven Announces Class Action Lawsuit on Behalf of Purchasers of Endocyte

Brower Piven announced that a class action lawsuit has been commenced in the United States District Court for the Southern District of Indiana on behalf of purchasers of Endocyte, Inc. common stock during the period between March 21, 2014 and May 2, 2014, inclusive, and informs investors who wish to become proactively involved in the litigation that they have until August 25, 2014 to seek appointment as lead plaintiff. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If wish to choose counsel to represent and the Class, must apply to be appointed lead plaintiff no later than August 25, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the large loss from investment in Company units during the Class Period.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECYT:US $6.08 USD -0.91

ECYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECYT.
View Industry Companies

Industry Analysis


Industry Average

Valuation ECYT Industry Range
Price/Earnings 20.3x
Price/Sales 2.9x
Price/Book 1.4x
Price/Cash Flow 21.9x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at